t(3;17)(q26;q22)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: July 2007

Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0317q26q22ID1282.html

DOI: 10.4267/2042/38532

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.

© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

t(3;17)(q26;q22) G-banding – Coutesy Melanie Zenger and Claudia Haferlach.

Clinics and pathology

Disease

Chronic myelogenous leukaemia with t(9;22)(q34;q11) and blast crisis of CML (BC-CML) (4 cases altogether), other myeloproliferative syndromes, Acute myeloid leukaemia (AML) in 4 cases (one M1, 2 therapy related AML, one of which after breast cancer).

Epidemiology

At least 9 cases to date, aged 62 years (median, range: 49-78); sex ratio was 5M/3F.

Prognosis

No data.

Cytogenetics

Cytogenetics morphological

Sole anomaly in 3 cases, with t(9;22)(q34;q11) in 4 cases (one of which was a complex translocation), with del(5q) (1 case), and with del(7q), and +21 in 1 case.

Genes involved and Proteins

Note: The partner of EVI1 is yet unknown.

EVI1

Location: 3q26.2

Protein

Transcription factor; EVI1 targets include: GATA2, ZBTB16/PLZF, ZFPM2/FOG2, JNK and the PI3K/AKT pathway. Role in cell cycle progression, likely to be cell-type dependant; antiapoptotic factor; involved in neuronal development organogenesis; role in hematopoietic differentiation.

References


This article should be referenced as such: